CONTINUING PHARMACY EDUCATION
What Lies Ahead: A Look at the Biosimilar, Infectious Diseases and
Specialty/Oncology Drug Pipeline in 2024-2025
Speaker:
SPEAKER: Liya Davydov, PharmD, BCPS, BCGP, Senior Director, Clinical Pharmacy Services (Continuum of Care Division), Premier Inc, Charlotte, NC
ACPE Universal Program ID# 0122-0000-24-061-H01-P/T
1 Contact Hours [0.1 CEU]
Release Date: August 12, 2024
Expiration Date: March 12, 2025
Fee
$0.00
CE Hours
1.00
CE Units
0.100
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists and Pharmacy Technicians
Accreditation(s)
Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
There are 2 steps to completing this home-study CE.
Step 1: Watch the video presentation in its entirety.
Step 2: Click on "Take the Test" to complete the post-test and evaluation.
Please Note: A handout is provided. Please print it out and follow along with the audio recording.
Objectives
- Identify biosimilar agents that have been recently approved, rejected or currently under regulatory review.
- List various reimbursement models/strategies for biosimilars.
- Identify notable agents that have been recently approved, rejected, in late stages of development or under regulatory review for infectious diseases indications.
- Identify specialty drugs currently under regulatory review for select indications.
- List oral and parenteral oncology agents currently under regulatory review for various cancers.
Activity Number
0122-0000-24-061-H01-P/T
Release Date:
Aug 12, 2024
Credit Expiration Date:
Mar 12, 2025
CE Hours
1.00